Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

Z
Zaborowski, Konrad

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Konrad Zaborowski
Favorite
Zaffaroni, Nadia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Nadia Zaffaroni
Favorite
Zah, Vladimir

ZRx Outcomes Research Inc.
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Vladimir Zah
Favorite
Zaidi, Shane

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Shane Zaidi
Favorite
Zając, Agnieszka

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Agnieszka Zając
Favorite
Zalcberg, John

School of Public Health, Faculty of Medicine, Monash University
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
John Zalcberg
Favorite
zama, mario

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
mario zama
Favorite
Zang, Jie

Peking University People's Hospital
(P 276) RECONSTRUCTION WITH TOTAL SCAPULAR REVERSE TOTAL SHOULDER ENDOPROSTHESIS: PRELIMINARY RESULTS FROM A SINGLE INSTITUTE
Jie Zang
Favorite
Zan, Pengfei

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Pengfei Zan
Favorite
Zapardiel, Ignazio

La Par University Hospital, Madrid
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Ignazio Zapardiel
Favorite
Zapata, Maycos

LACOG
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Maycos Zapata
Favorite
Zarifa, Abdulrazzak

Endeavor Health
(P 247) THE REAL-WORLD EFFICACY OF IMMUNE CHECKPOINT INHIBITORS WITH CONCURRENT RADIATION OR SURGERY IN MULTIMODAL TREATMENT OF SOFT TISSUE SARCOMAS: A RETROSPECTIVE STUDY
Abdulrazzak Zarifa
Favorite
Zarzour, Alex

The University of Texas MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Alex Zarzour
Favorite
Zdzienicki, Marcin

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Marcin Zdzienicki
Favorite
Zebley, Caitlin

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Caitlin Zebley
Favorite
Zeedyk, Kaitlin

Atlantic Health System
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Kaitlin Zeedyk
Favorite
Zemp, Franz

Arnie Charbonneau Cancer Institute and McCaig Institute for Bone and Joint Health
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Franz Zemp
Favorite
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Franz Zemp
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Franz Zemp
Favorite
Zenda, Sadamoto

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Sadamoto Zenda
Favorite
Zervoudakis, Guston

Moffitt Cancer Center
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Guston Zervoudakis
Favorite
Zhang, Ali

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Ali Zhang
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Ali Zhang
Favorite
Zhang, Chen-Lu

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Chen-Lu Zhang
Favorite
Zhang, Daiyao

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Daiyao Zhang
Favorite
Zhang, Ellen

Stanford Health Care
(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
Ellen Zhang
Favorite
(P 214) REPRESENTATION OF CHILDREN AND OLDER ADULTS IN SARCOMA CLINICAL TRIALS SINCE THE INCLUSION ACROSS THE LIFESPAN POLICY
Ellen Zhang
Favorite
(P 215) REPRESENTATION OF RACIAL AND ETHNIC MINORITIES IN SARCOMA CLINICAL TRIALS
Ellen Zhang
Favorite
Zhang, Jianhua

The University of Texas MD Anderson Cancer Center
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Jianhua Zhang
Favorite
zhang, jun

Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
jun zhang
Favorite
Zhang, Lihong

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Lihong Zhang
Favorite
Zhang, Lindy

Johns Hopkins School of Medicine
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Lindy Zhang
Favorite
Zhang, Lingxin

Mount Sinai Hospital/University of Toronto
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Lingxin Zhang
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Lingxin Zhang
Favorite
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Lingxin Zhang
Favorite
Zhang, Liuzhe

University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Department of Surgery, University of Toronto, Toronto, Canada
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Liuzhe Zhang
Favorite
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Liuzhe Zhang
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Liuzhe Zhang
Favorite
Zhang, Peng

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
(P 97) TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
Peng Zhang
Favorite
Zhang, Ranxin

Montefiore Medical Center/ Albert Einstein College of Medicine
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
Ranxin Zhang
Favorite
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Ranxin Zhang
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Ranxin Zhang
Favorite
Zhang, Wei

Wake Forest
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Wei Zhang
Favorite
Zhang, xiaochun

Washington University in St. Louis School of Medicine
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
xiaochun Zhang
Favorite
(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
xiaochun Zhang
Favorite
Zhang, Xing

Sun Yat-Sen University Cancer Center
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Xing Zhang
Favorite
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Xing Zhang
Favorite
Zhang, Xinhua

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Xinhua Zhang
Favorite
Zhang, yiqun

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
yiqun Zhang
Favorite
Zhang, Yong

Department of surgical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Yong Zhang
Favorite
Zhao, Lei

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Lei Zhao
Favorite
Zhao, Weisong

Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Weisong Zhao
Favorite
Zheng, Deyou

Albert Einstein College of Medicine
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
Deyou Zheng
Favorite
Zheng, Jing

The University of Texas M D Anderson Cancer Center
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Jing Zheng
Favorite
Zhou, Bo

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Bo Zhou
Favorite
Zhou, Maggie

Stanford University School of Medicine
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Maggie Zhou
Favorite
(P 161) UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA
Maggie Zhou
Favorite
Zhou, Yong

Department of Orthopedics, West China Hospital, Sichuan University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Yong Zhou
Favorite
Zhou, Yuhong

Oncology Department Zhongshan Hospital
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Yuhong Zhou
Favorite
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Yuhong Zhou
Favorite
Zhuang, Rong-Yuan

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Rong-Yuan Zhuang
Favorite
Zhu, Dong-Lei

Clinical Development, Boehringer Ingelheim, Shanghai, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Dong-Lei Zhu
Favorite
Zhu, Limin

OHSU
(P 227) EFFICACY OF IMMUNOTHERAPY IN TREATING METASTATIC MALIGNANT MYOPERICYTOMA: A CASE REPORT AND RIVEW OF LITERATURE
Limin Zhu
Favorite
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Limin Zhu
Favorite
Ziaee, Maryam

µFO Lab, Polytechnique Montréal, Montréal, Canada; Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada; Institut du Cancer de Montréal (ICM), Montréal, Canada
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Maryam Ziaee
Favorite
Ziegler, David S.

Sydney Children’s Hospital, Randwick, NSW, Australia and School of Women’s and Children’s Health, University of New South Wales Sydney
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
David S. Ziegler
Favorite
Zijlmans, Henry

Netherlands Cancer Institute
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Henry Zijlmans
Favorite
Zilla, Megan

University of Pittsburgh Medical Center
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Megan Zilla
Favorite
Zoccali, Carmine

Università “La Sapienza” di Roma
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Carmine Zoccali
Favorite
Zon Filippi, Renee

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Renee Zon Filippi
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Renee Zon Filippi
Favorite
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Renee Zon Filippi
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Renee Zon Filippi
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Renee Zon Filippi
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Renee Zon Filippi
Favorite
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Renee Zon Filippi
Favorite
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Renee Zon Filippi
Favorite
Zuckerman, Lee

Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California
(P 197) EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES
Lee Zuckerman
Favorite
(P 259) COMPRESSION OF INTERCALARY ALLOGRAFTS WITH MAGNETIC LENGTHENING NAILS, MID-TERM RESULTS WITH A COMPARISON OF TECHNIQUES
Lee Zuckerman
Favorite
Zuco, Valentina

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Valentina Zuco
Favorite
ZUGMAN, MIGUEL

City of Hope Cancer Center
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
MIGUEL ZUGMAN
Favorite
Zuo, Dongqing

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Dongqing Zuo
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Dongqing Zuo
Favorite
Zyczynski, Laurie

University of Michigan
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Laurie Zyczynski
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Laurie Zyczynski
Favorite